Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

March 30, 2024

Study Completion Date

June 1, 2024

Conditions
Pancreatitis, Acute
Interventions
DRUG

Placebo treatment

Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.

DRUG

Naldemedine 0.2 MG Oral Tablet

Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.

Trial Locations (5)

9000

Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital, Aalborg

Unknown

Digestive Disease Center K, Bispebjerg University Hospital, Bispebjerg

Gastrounit, Hvidovre University Hospital, Hvidovre

Odense Pancreas Center, Svendborg

SE-171 76

Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Odense University Hospital

OTHER

collaborator

Hvidovre University Hospital

OTHER

collaborator

University Hospital Bispebjerg and Frederiksberg

OTHER

collaborator

Karolinska University Hospital

OTHER

lead

Asbjørn Mohr Drewes

OTHER